Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Emily P. Slater

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5109064936, A5109084789. Sources: OpenAlex.

Their work

Papers
24 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 5 papers · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers

Papers 24

  1. Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant-negative familial pancreatic … Co-author DOI 10.1002/ueg2.12631↗
  2. Joint Linkage and Association Analysis Using GENEHUNTER-MODSCORE with an Application to Familial Pancreatic Cancer. Co-author DOI 10.1159/000535840↗
  3. Dissecting the role of toll-like receptor 7 in pancreatic cancer. Co-author DOI 10.1002/cam4.5606↗
  4. Characteristics of familial pancreatic cancer families with additional colorectal carcinoma. Co-author DOI 10.1007/s10689-023-00328-1↗
  5. Proteomics biomarker discovery for individualized prevention of familial pancreatic cancer using statistical learning. Co-author DOI 10.1371/journal.pone.0280399↗
  6. Effects of Monoamino-Oxidase-A (MAO-A) Inhibition on Skeletal Muscle Inflammation and Wasting through Pancreatic Ductal Adenocarcinoma in Triple Transgenic Mic… Co-author DOI 10.3390/biomedicines11030912↗
  7. Inflammation and Wasting of Skeletal Muscles in Kras-p53-Mutant Mice with Intraepithelial Neoplasia and Pancreatic Cancer-When Does Cachexia Start? Co-author DOI 10.3390/cells11101607↗
  8. PRMT1 promotes the tumor suppressor function of p14ARF and is indicative for pancreatic cancer prognosis. Co-author DOI 10.15252/embj.2020106777↗
  9. The German National Case Collection for Familial Pancreatic Carcinoma (FaPaCa)—Knowledge Gained in 20 Years. Last author DOI 10.3238/arztebl.m2021.0004↗
  10. Extracellular Vesicle-Based Detection of Pancreatic Cancer. Last author DOI 10.3389/fcell.2021.697939↗
  11. Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma. Co-author DOI 10.3390/jpm11020113↗
  12. Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer. Co-author DOI 10.3390/jpm11070631↗
  13. The Immune Microenvironment in Pancreatic Cancer. Co-author DOI 10.3390/ijms21197307↗
  14. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic inj… Co-author DOI 10.1038/s41388-017-0100-4↗
  15. German National Case Collection for familial pancreatic Cancer (FaPaCa) - acceptance and psychological aspects of a pancreatic cancer screening program. Co-author DOI 10.1186/s13053-018-0100-6↗
  16. The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. Last author DOI 10.3390/jcm7100295↗
  17. Refinement of screening for familial pancreatic cancer. First author DOI 10.1136/gutjnl-2015-311098↗
  18. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Co-author DOI 10.1200/jco.2015.64.0730↗
  19. Limited resection of pancreatic cancer in high-risk patients can result in a second primary. Co-author DOI 10.1136/gutjnl-2015-309568↗
  20. MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2014.05.007↗
  21. Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade … Co-author DOI 10.1007/s10689-012-9582-y↗
  22. Variation in precursor lesions of pancreatic cancer among high-risk groups. Co-author DOI 10.1158/1078-0432.ccr-12-2730↗
  23. LCN2 and TIMP1 as Potential Serum Markers for the Early Detection of Familial Pancreatic Cancer. Co-author DOI 10.1593/tlo.12373↗
  24. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. First author DOI 10.1007/s10689-010-9414-x↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Detlef Klaus Bartsch · 21 shared papers, 2011–2024 · strength 2.14
  2. Thomas Mathias Gress · 8 shared papers, 2013–2024 · strength 0.75
  3. Konstantin Strauch · 6 shared papers, 2013–2024 · strength 0.68
  4. Volker Fendrich · 8 shared papers, 2011–2023 · strength 0.57
  5. Bettina Lehman · 2 shared papers, 2023–2024 · strength 0.40
  6. Peter Langer · 8 shared papers, 2011–2021 · strength 0.39
  7. Yesim Verel‐Yilmaz · 3 shared papers, 2021 · strength 0.36
  8. Jörg Walter Bartsch · 3 shared papers, 2020–2021 · strength 0.36
  9. Simon K. P. Schmich · 2 shared papers, 2022–2023 · strength 0.32
  10. Wulf Hildebrandt · 2 shared papers, 2022–2023 · strength 0.32
  11. Ralf Kinscherf · 2 shared papers, 2022–2023 · strength 0.32
  12. Christian Alexander Bauer · 3 shared papers, 2018–2021 · strength 0.31
  13. Elke Pogge von Strandmann · 3 shared papers, 2018–2021 · strength 0.29
  14. Corinna Ulrike Keber · 2 shared papers, 2021–2023 · strength 0.27
  15. Malte Buchholz · 2 shared papers, 2020–2023 · strength 0.27
  16. Christian Peter Jaworek · 2 shared papers, 2021 · strength 0.25
  17. Markus Brugger · 1 shared paper, 2024 · strength 0.23
  18. Günter Klöppel · 5 shared papers, 2013–2018 · strength 0.22
  19. Elisabeth Maurer · 1 shared paper, 2024 · strength 0.21
  20. Ioannis Mintziras · 2 shared papers, 2018–2021 · strength 0.20
  21. Chung Shing Rex Ha · 1 shared paper, 2023 · strength 0.19
  22. Matthias Lauth · 2 shared papers, 2018–2020 · strength 0.18
  23. Bert A. Bonsing · 4 shared papers, 2013–2016 · strength 0.17
  24. Hans F. A. Vasen · 4 shared papers, 2013–2016 · strength 0.17
  25. Frederike S. Franke · 2 shared papers, 2018 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.